Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® ...

Otulfi (ustekinumab-aauz) is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play an important role in inflammatory and immune responses. The FDA ...

Stelara is a monoclonal antibody designed to block the activity of the interleukin 12 and interleukin 23 molecules in the immune system, which are involved in inflammation and other processes that ...

J&J’s pharma unit Janssen said Stelara is the first interleukin-12/23 inhibitor to be approved for UC, an inflammatory bowel disease which affects around 2.6 million people in Europe.

Recent reports have now implicated interleukin 12 and interleukin 23 ... The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of ...

The anti-TNF era was followed by the emergence of interleukin (IL) inhibitors, with J&J’s Stelara (ustekinumab) leading the way in 2019. This therapy, initially thought to owe its efficacy to ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

Stelara, also known as ustekinumab, is a monoclonal antibody that targets specific proteins called interleukin-12 (IL-12) and interleukin-23 (IL-23). Interleukins are signal molecules of the ...

The aim of this observational post-authorization safety study was to assess the comparative cardiovascular safety of ustekinumab, an interleukin-12/23 inhibitor, using robust national registry data ...